The effectiveness of CD47 blockade also following gefitinib treatment, as shown in our experiments in vitro, supports the development of therapeutic strategies in which anti-CD47 immunotherapy and target therapy may be combined to minimize the development of resistant clones responsible for tumor relapse. This evidence concerns the gene CD47 and neoplasm.